Chondroprotec is a Patented Topical Wound Management Dressing
Polysulfated glycosaminoglycan (PSGAG)
Chondroprotective agents are natural substances such as glycosaminoglycans that support or enhance the connective tissue matrix and, as such, are found in the chemical composition of connective tissue and soft tissue in humans and animals. These compounds have become beneficial in the management of chronic and acute wounds. Polysulfated glycosaminoglycans (PSGAG) rehydrate dry wounds, maintain a moist healing environment, 1-2-3 and protect from tissue trauma2. CHONDROPROTEC ® is the only product cleared for use on traumatic injuries, such as corneal ulcers (for more information visit our BLOG section for the article discussing such use).
Hymed® is currently seeking qualified distributors for this product to the medical marketplace. Hymed® has developed a proprietary gel formula including hydrolyzed collagen (branded as Hyprotec, see Products tab for more information) for wound care applications utilizing this PSGAG chemistry. If you are interested in distributing this product, please fill out the Distributor questionnaire in the Distributors section and fax to: 610-691-5930 or you may call with inquiries: 610-865-9876.
“Glycosaminoglycans: Their Role in Wound Management” by George D. Petito, Ph.D.
“Effects of PSGAG in conjunction with an occlusive or non-occlusive dressing in preparing granulation tissue for re-epithelialization.”
“The Effect of CHONDROPROTEC ® (a polysulfated glycosaminoglycan) on wound healing.”
Please click here to visit Neogen Corporation website (Our veterinary distributor for CHONDROPROTEC ®)
If you are interested in purchasing CHONDROPROTEC ® for veterinary use, contact Neogen Corporation at 800-525-2022.
- Lassus, A. Jeskahen, L., et al: Imdeen for the treatment of degenerated skin in females. Journal of Int=l Research. 19(2): 147-52.
- Cooper, ML, Hansbrough, JF. Use of a composite skin graft composed of fibroblasts and a collagen-GAG matrix to cover full- thickness wounds. Surgery. Feb. 1991; 109(2): 198-207.
- Breborowitz, A. , et al: Glycosaminoglycan chondroitin sulfate prevent loss of ultra filtration during peritoneal dialysis in rats. Nephron. 1994; 67(3): 346-50.
The information given herein is believed to be reliable. However, no guarantee is made or liability assumed. The Hymed Group Corporation does not know all of the uses to which its products may be utilized or the condition of use. Therefore, The Hymed Group Corporation makes no claims or warranty concerning the fitness or suitability of the product for a particular use or purpose other than those outlined.